Photo: skynesher/Getty Images
AI safety and research company Anthropic is partnering with international biotech company Genmab to build custom Claude-powered agentic AI capabilities aligned with Genmab's research and development processes.
Anthropic's AI assistant and large language model (LLM), Claude, will be used by Genmab's team for data processing, analysis and document generation, with human oversight and guardrails, to assist with operational activities and improve consistency within clinical programs.
"Clinical development is critical, heavily regulated and directly tied to patient outcomes. This is why we’re partnering with an innovative and patient-focused biotech company like Genmab as they apply AI to support their clinical development process," Kate Jensen, head of Americas at Anthropic, said in a statement.
"We're working closely with Genmab to deploy Claude and build custom agentic solutions with the intention to help their team focus on the hard problems that require human expertise and get therapies to patients faster."
Hippocratic AI, a generative AI company focused on administrative healthcare tasks, is partnering with global consulting firm Boston Consulting Group (BCG) to help the biopharma and medtech industries implement generative AI healthcare agents.
Hippocratic AI's generative AI focuses on nondiagnostic healthcare tasks such as medication onboarding, monthly reconciliation, answering hospital and payer policy questions, and providing EHR assistance.
The companies said the partnership will combine Hippocratic AI's and BCG's expertise to help life sciences organizations generate value from AI technology and move from experimentation to enterprise-scale impact.
"Our collaboration with BCG is built on a shared commitment to improving patient outcomes," Munjal Shah, founder and CEO of Hippocratic AI, said in a statement.
"By combining BCG’s deep strategic and operational expertise with our safety-focused generative AI health care agents, we can accelerate innovation across biopharma and medtech, bringing scalable, empathetic, and clinically aligned support to patients, providers, and researchers around the world."
Real-world clinical data analytics company Verana Health has merged with oncology-focused data company COTA.
Verana Health combines clinical expertise with real-world data to help providers access real-world evidence and obtain clinical insights.
COTA focuses specifically on cancer care data, offering oncology research and development, regulatory, commercial, and health economics and outcomes research (HEOR) teams with patient data to help discover new treatment protocols for cancer care.
Verana said in a statement that the merger adds high-fidelity oncology datasets and analytics to its offerings and strengthens its relationships within the biopharma industry, as the combined company will serve 17 of the top 20 global biopharma companies.
"This is a unique opportunity to better serve organizations with advanced curation technology and real-world insights across multiple specialty therapeutic areas. This combination raises the bar for clinical expertise, data quality, validation, and transparency, so our partners can generate evidence with the utmost confidence," Sujay Jadhav, CEO of Verana Health, said in a statement.
